Literature DB >> 15963086

Personalized drug therapy; the genome, the chip and the physician.

Lionel D Lewis.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15963086      PMCID： PMC1884905          DOI： 10.1111/j.1365-2125.2005.02457.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  34 in total

1.  CYP2C9 polymorphism and warfarin dose requirements.

Authors:  Ann K Daly; Christopher P Day; Guruprasad P Aithal
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

Review 2.  Pharmacogenetics of oral anticoagulants.

Authors:  Ann K Daly; Barry P King
Journal:  Pharmacogenetics       Date:  2003-05

3.  Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

Authors:  A Holstein; A Plaschke; M Ptak; E-H Egberts; J El-Din; J Brockmöller; J Kirchheiner
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

4.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Authors:  D Dai; D C Zeldin; J A Blaisdell; B Chanas; S J Coulter; B I Ghanayem; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-10

Review 5.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

Authors:  Craig R Lee; Joyce A Goldstein; John A Pieper
Journal:  Pharmacogenetics       Date:  2002-04

6.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

Review 7.  Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors:  J A Goldstein
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

Review 8.  Pharmacogenomics: the inherited basis for interindividual differences in drug response.

Authors:  W E Evans; J A Johnson
Journal:  Annu Rev Genomics Hum Genet       Date:  2001       Impact factor: 8.929

Review 9.  Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.

Authors:  T Furuta; N Shirai; K Ohashi; T Ishizaki
Journal:  Methods Find Exp Clin Pharmacol       Date:  2003-03

10.  Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.

Authors:  Norio Yasui-Furukori; Takenori Takahata; Taku Nakagami; Gen Yoshiya; Yoshimasa Inoue; Sunao Kaneko; Tomonori Tateishi
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335
View more
  6 in total

1.  Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.

Authors:  Yuanyuan Dong; Huasheng Xiao; Qi Wang; Chunxiu Zhang; Xiuming Liu; Na Yao; Haihui Sheng; Haiyan Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 2.  The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Drug development in oncology: classical cytotoxics and molecularly targeted agents.

Authors:  Shivaani Kummar; Martin Gutierrez; James H Doroshow; Anthony J Murgo
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

Review 4.  Population genetic considerations for using biobanks as international resources in the pandemic era and beyond.

Authors:  Hannah Carress; Daniel John Lawson; Eran Elhaik
Journal:  BMC Genomics       Date:  2021-05-17       Impact factor: 3.969

5.  Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis.

Authors:  Han Chen; Yini Dang; Xiaoying Zhou; Bingtuan Liu; Shiyu Liu; Guoxin Zhang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 6.  Nucleic Acid Aptamers for Molecular Therapy of Epilepsy and Blood-Brain Barrier Damages.

Authors:  Tatiana N Zamay; Galina S Zamay; Natalia A Shnayder; Diana V Dmitrenko; Sergey S Zamay; Victoria Yushchenko; Olga S Kolovskaya; Vanessa Susevski; Maxim V Berezovski; Anna S Kichkailo
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-15       Impact factor: 8.886
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.